Sequella Drug Candidate SQ109 Named as One of 100 Great Investigational Drugs in R&D Directions Article

Sequella, Inc. 9610 Medical Center Drive Rockville, MD 20850 Tele: 301-762-7776 www.sequella.com NEWS RELEASE April 4, 2007 SEQUELLA DRUG CANDIDATE SQ109 NAMED AS ONE OF 100 GREAT INVESTIGATIONAL DRUGS IN R&D DIRECTIONS ARTICLE ROCKVILLE, MD – Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing improved treatment paradigms for diseases of epidemic potential, and its lead clinical drug candidate, SQ109, was cited in the March 2007 Issue of R& D Directions as one of the 100 great investigational drugs of 2007. It was the only new tuberculosis drug to make the list. SQ109, Sequella’s lead drug candidate, is an orally active small-molecule antibiotic that inhibits cell wall synthesis in a select group of microorganisms, including M. tuberculosis . SQ109 has received Fast Track status from the FDA and is in Phase I clinical trials. The R& D Directions report can be found at http://www.pharmalive.com/magazines/randd/ . For more information on Sequella visit www.sequella.com . ### About Tuberculosis TB is a contagious infectious disease caused by the bacterium Mycobacterium tuberculosis . Infection is usually caused by inhaling the bacteria. When the bacteria are not controlled or eliminated by the person’s immune system, the bacteria can multiply and spread throughout the body causing infection in other organs such as the kidneys, brain, and bones. TB bacteria can survive and remain dormant in the infected person for years, causing recurrent disease long after the initial infection. More than nine million new cases of active TB disease are reported every year. The World Health Organization (WHO) estimates that one-third of the world’s population is infected with TB. MEDIA CONTACT: Alicia Moran, 703-739-2424 x110 or [email protected]

The release as fetched from its publisher. sequella.com ↗